DRW Securities LLC Invests $1.94 Million in Illumina, Inc. (NASDAQ:ILMN)

DRW Securities LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,594 shares of the life sciences company’s stock, valued at approximately $1,941,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Trivant Custom Portfolio Group LLC lifted its position in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after buying an additional 125 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina during the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV increased its stake in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Principal Securities Inc. bought a new stake in shares of Illumina in the fourth quarter valued at approximately $51,000. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of Illumina stock opened at $131.20 on Friday. The firm has a market capitalization of $20.90 billion, a PE ratio of -16.10 and a beta of 1.15. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $148.19. The business’s 50-day moving average price is $125.25 and its 200-day moving average price is $120.57.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period last year, the business earned $0.32 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 3.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ILMN. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Jefferies Financial Group started coverage on Illumina in a research report on Monday, June 3rd. They issued a “hold” rating and a $115.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $242.00 price objective on shares of Illumina in a report on Wednesday, August 14th. Scotiabank reduced their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Finally, Robert W. Baird upped their price target on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $151.05.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.